Vanguard Capital Management’s ClearPoint Neuro CLPT Stock Holding History
Bought
Maintained
Sold
Other funds holding CLPT
Vanguard Capital Management's CLPT Position: Q3 2026 in Review
Vanguard Capital Management reduced its ClearPoint Neuro (CLPT) stake by 0.14% in Q3 2026, selling an estimated $26.5K and leaving 1,231,045 shares worth $15M. The position accounts for ﹤0.01% of the portfolio, ranked #2549.
Vanguard Capital Management first reported a position in CLPT in Q1 2026 and has held it in 3 quarters since. The position peaked at $22M in Q2 2026. 126 funds tracked by Wall St. Rank hold CLPT as of Q3 2026.
- Vanguard Capital Management held 1,231,045 shares of ClearPoint Neuro worth $15M as of Q3 2026.
- Vanguard Capital Management sold 1,762 ClearPoint Neuro shares in Q3 2026, an estimated $26.5K.
- ClearPoint Neuro made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2549 holding.
- Vanguard Capital Management first reported a position in ClearPoint Neuro in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's ClearPoint Neuro position peaked at $22M in Q2 2026.
- 126 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.